Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 先聲藥業集團有限公司 (於香港註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 不適用 備註： 本公司乃於香港註冊成立。根據香港《公司條例》(第 622 章)，在香港註冊成立的公司沒有法定股本，因此並無"面值"的概念。 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年10月31日 狀態: 新提交 FF301 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） 不適用 第 3 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02096 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown significant market activity, with a recent increase of 3.38% and a trading volume of 170 million yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) reached a new high in both scale and shares since its inception as of October 31 [1] - The ETF has experienced net inflows for 4 out of the last 5 trading days, totaling 18.9 million yuan [1] - The index it tracks, the National Certificate Hong Kong Stock Connect Innovative Drug Index, rose by 3.67%, with notable increases in component stocks such as Senhwa Biosciences (up 10.11%) and Kanglongda (up 8.80%) [1] Group 2: Policy and Industry Insights - The ongoing negotiations for the National Medical Insurance drug list are complemented by a new commercial health insurance innovative drug directory, aimed at providing new payment channels for high-value innovative drugs [1] - The CAR-T cell drug, Rukiyou Lunsai injection from WuXi AppTec, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, with a listed price of 1.29 million yuan per injection [1] - Open Source Securities notes that the current innovative drugs included in both medical insurance and commercial insurance are in the early stages of volume growth, with potential for rapid revenue increases as policies continue to support innovative drugs [2] Group 3: Institutional Investment Trends - According to Guotou Securities, the proportion of all funds heavily invested in Biotech innovative drug companies has increased to 27.53%, reflecting a 2.61 percentage point rise, indicating growing institutional interest in the innovative drug sector [2] - The increasing allocation of funds to the innovative drug sector suggests a strong market recognition of its long-term development potential [2]

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector is showing resilience, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 1.40% as of November 3, 2025, driven by positive developments in the industry [1]. Group 1: Market Performance - The index's performance is highlighted by significant gains in constituent stocks, including 康诺亚-B (02162) up 5.73%, 先声药业 (02096) up 5.66%, and 康方生物 (09926) up 5.29% [1]. - Other stocks such as 一脉阳光 (02522) and 平安好医生 (01833) also experienced upward movement, indicating a broader positive trend in the sector [1]. Group 2: Industry Developments - The introduction of the "Commercial Insurance Innovative Drug Directory" marks a significant policy shift, as it is the first time this mechanism has been officially included in the national discussions on medical insurance [1]. - Pfizer has initiated two global Phase III clinical trials for its PD-1/VEGF bispecific antibody SSGJ-707 (PF-08634404), targeting first-line treatment for non-small cell lung cancer and colorectal cancer, which is expected to enhance the sector's growth prospects [1]. Group 3: Future Outlook - Research indicates that the pharmaceutical and biotechnology industry is entering a new upward cycle, with accelerated overseas orders and strong upward momentum, particularly benefiting biopharmaceutical companies with robust international capabilities [1].

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced a significant rebound on November 3, with the innovative drug ETF (520880) showing a volatility of over 4.4% and a trading volume exceeding 500 million yuan, indicating strong bullish sentiment [1] - Key stocks such as Kangfang Biotech, Xiansheng Pharmaceutical, and Kangnuo Ya-B saw increases of nearly 6%, while other companies like Yuanda Pharmaceutical and Rongchang Biotech also experienced substantial gains [1] - The National Medical Insurance negotiation, which began on October 30, is expected to conclude with results announced in early December, introducing a new "commercial insurance innovative drug catalog" mechanism for the first time [1] Group 2 - Fund manager Feng Chen indicated that the innovative drug market could see a resurgence, suggesting that now may be a high-probability period for medium to long-term investments in innovative drugs [2] - The recent meeting between US and Chinese leaders has alleviated previous risks that suppressed the sector's performance, potentially allowing previously withdrawn funds to re-enter the market [2] - The current earnings season has shown strong performance from companies like Innovent Biologics and Hengrui Medicine, boosting confidence in the sector [2] Group 3 - The Hong Kong Stock Connect innovative drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses entirely on innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [3] - As of the end of September, the index has seen a year-to-date increase of 108.14%, outperforming other innovative drug indices [3] - The ETF has a fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan, making it the largest and most liquid ETF tracking this index [3]

Market Overview - The Hong Kong stock market showed a mixed performance with the Hang Seng Index closing down 0.24% at 26,282.69, the Hang Seng China Enterprises Index down 0.31% at 9,346.86, and the Hang Seng Tech Index down 0.68% at 6,051.76 [1][2] - Southbound funds recorded significant net purchases exceeding 11 billion HKD, with net purchases of 6.612 billion HKD through the Shanghai-Hong Kong Stock Connect and 7.03 billion HKD through the Shenzhen-Hong Kong Stock Connect [2] Sector Performance - Large technology stocks exhibited divergent trends, with Baidu, Bilibili, and NetEase each falling over 2%, while Meituan rose over 2% [4][6] - The lithium battery sector performed strongly, with Ganfeng Lithium surging nearly 15% after reporting better-than-expected earnings [4][12] - Coal stocks, port and shipping stocks, photovoltaic stocks, nuclear power stocks, home appliance stocks, and building materials stocks were mostly active [4] Notable Stocks - Ganfeng Lithium reported a revenue of 14.625 billion CNY for the first three quarters of 2025, a year-on-year increase of 5.02%, and a net profit of 25.52 million CNY, recovering from a loss of 640 million CNY in the previous year [12] - In the healthcare sector, innovative drug stocks declined, with companies like Xiansheng Pharmaceutical and Innovent Biologics dropping over 4% [9] - Real estate stocks faced downward pressure, with China Overseas Macro Group and R&F Properties falling 5% [10] Commodity Performance - Gold and precious metals saw significant gains, with companies like Zijin Mining and China Silver Group rising over 8% [11] - The World Gold Council reported a 3% year-on-year increase in global gold demand for Q3 2025, reaching 1,313 tons, marking the highest quarterly demand on record [11] Economic Outlook - Morgan Asset Management indicated that a moderate expansion of the U.S. economy and gradually declining interest rates could benefit risk assets, particularly in the technology, communication services, and financial sectors [14] - The Federal Reserve's interest rate cuts are expected to enhance global liquidity, potentially supporting non-U.S. markets [14]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：2096） 進一步修訂獨家推廣服務合作協議的 2025年及2026年年度上限 茲提述先聲藥業集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）日 期為2023年12月29日、2024年1月17日及2025年1月24日的公告（「該等公告」）。 除另有界定外，本公告所用詞彙與該等公告所界定者具有相同涵義。 誠如該等公告所披露，於2023年12月29日，江蘇先聲與北京先聲祥瑞訂立獨家推 廣服務合作協議，據此，江蘇先聲同意授予北京先聲祥瑞於推廣適應症範圍及於 推廣區域內推廣本集團仿製藥（即富馬酸貝達喹啉片）的獨家推廣權。獨家推廣服 務合作協議自2024年1月16日北京先聲祥瑞股東大會批准之日起生效，有效期至 2026年12月31日止。 –1– 誠如該等公告所披露，截至2025年及2026年12月31日止兩個年度獨家推廣服務合 作協議項下的原年度上限修訂如下（「首 ...

Core Insights - The company has successfully reduced the price of the innovative drug Koserla from $1,400 to 466 RMB, significantly benefiting patients in China [2] - The accelerated commercialization process of Koserla, taking only 13 months instead of the traditional 3 years, is attributed to the Boao Lecheng International Medical Tourism Pilot Zone's real-world data pilot program [2] - The local production of Koserla in Haikou is expected to enhance affordability and accessibility for patients, with an annual production capacity of 2 million units [3] - The company aims to leverage the Hainan Free Trade Port policies to expedite the international licensing of its self-developed products, with a total contract value of 745 million RMB for its first overseas project [3] Company Strategy - The company is utilizing the "Lecheng Research and Use + Haikou Production" model to integrate industrial foundations with policy advantages, facilitating the local production of international innovative drugs [3] - The company has already achieved three overseas patent technology authorizations for its self-developed products since the establishment of the Hainan Free Trade Port [3] - A significant drug export project worth several hundred million RMB is expected to be completed by the end of this year [3]

Market Overview - Recent reactions to China's rare earth measures have led to significant declines in global stock markets, with major Asian markets dropping sharply, particularly in Japan and Taiwan, which fell over 1% [1] - In the U.S., regional banks Zions Bancorp and Western Alliance Bancorp reported losses due to fraudulent commercial mortgage investments, causing their stock prices to plummet by 13% and 11% respectively, triggering widespread panic in the banking sector [1] - The fear index VIX has risen above 25 for the first time in five months, indicating increased market anxiety [1] Commodity Insights - Gold prices have surged past $4,300, with a total market capitalization exceeding $30 trillion, leading to strong performances in gold jewelry stocks such as Chow Tai Fook and Lao Poo Gold, which rose over 5% and 3% respectively [2] - In contrast, oil prices have declined significantly, with WTI crude oil falling to $56.99 per barrel, a drop of 2.3%, attributed to decreased consumption and increased production from OPEC and the U.S. [3] Sector Focus - The logistics sector is being prioritized for cost reduction and efficiency improvements, with a focus on building a modern logistics system that integrates digital infrastructure and supports small and micro enterprises [6] - Companies like Jitu Express and SF Express are highlighted as key players in the logistics market [7] Company Developments - Xiansheng Pharmaceutical Group has completed the first patient dosing in a Phase I clinical trial for its innovative cancer drug SIM0505 in the U.S., which targets advanced solid tumors [8] - The company reported a 15.1% year-on-year revenue growth to 3.585 billion yuan, driven by its innovative drug business, which accounted for 77.4% of total revenue [9] - The company has multiple innovative drugs in the pipeline, with significant potential for future growth, including two new drug applications expected to be submitted within the next 1-2 years [9]

Group 1: Hong Kong Stock Market - Changfei Optical Fiber Cable (06869) fell over 4%, down more than 40% from its September peak due to declining fiber optic prices and shareholder sell-offs [1] - Solar stocks continued to decline, with Fuyao Glass (03606) down over 3%, New Special Energy (01799) down over 5%, Xinyi Solar (00968) down over 5%, and Folaite Glass (06865) down over 4%. Rumors about the establishment of a polysilicon storage platform were found to be untrue, and future installation demand remains to be observed [2] Group 2: US Stock Market - United Airlines (UAL.US) fell 5.63% after reporting third-quarter revenue slightly below market expectations [3] - TSMC (TSM.US) decreased by 1.60%, with Q3 net profit reaching a record high of 452.3 billion New Taiwan dollars [3] - Micron Technology (MU.US) rose 5.52% as Morgan Stanley upgraded its rating from "hold" to "buy" [4] Group 3: Technology and Innovation - Google (GOOGL.US) increased by 0.17% after launching a new video generation model, Veo 3.1, which improved audio output and editing control [4] - Thermo Fisher Scientific (TMO.US) rose 1.69% as it collaborates with OpenAI to enhance drug development speed and success rates [4] Group 4: Other Notable Movements - DoorDash (DASH.US) fell 2.18% after announcing a partnership with Waymo to launch autonomous delivery services [5] - Derin Holdings (01709) rose over 3% after signing a strategic cooperation agreement with Antalpha to promote digital asset business [5] - NIO-SW (09866) increased over 2% after responding to a lawsuit from a Singapore sovereign wealth fund, stating that the allegations have no factual basis [5]